This trial is enrolling by invitation!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Multiple Sclerosis
and you are
between 18 and 60
years old
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

This is a Phase IV, prospective, open-label, single-center, observational, longitudinal, single blinded study. The investigators will examine the effects of Ocrelizumab on cognitive, patient reported outcomes (PROs), quality of life (QoL), multiple sclerosis functional composite (MSFC), working status and magnetic resonance imaging (MRI) outcomes across 12 and 24 months.

Provided treatments

  • Drug: Ocrelizumab
Tris trial is registered with FDA with number: NCT03025269. The sponsor of the trial is University at Buffalo and it is looking for 30 volunteers for the current phase.
Official trial title:
Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis